Risk factors

Clinical-stage biopharmaceutical company with no approved products, generating zero revenue and significant net losses.

Clinical-stage biopharmaceutical company dependent entirely on the regulatory approval and commercialization of ABP-450 as a biosimilar to Botox. Relies heavily on exclusive licensing and supply agreements with Daewoong for ABP-450 manufacturing and distribution. Faces significant financial risk with limited operating history, only five employees, and substantial accumulated losses.

Centurion Acquisition Corp. is a blank check company formed to complete an initial business combination. Risks focus on blank check mechanics, trust account preservation, shareholder redemptions, and sponsor control.

The company relies heavily on its external Manager and affiliates for sourcing non-QM loans and management services. Portfolio value and operations are exposed to interest rate volatility, residential mortgage market conditions, and credit risks. Investments span non-QM loans, residential and commercial mortgage-backed securities, and alternative credit assets.

Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on unproven NK cell-based therapies with no approved commercial products.

Aura Biosciences relies heavily on the single product candidate bel-sar for treating early-stage choroidal melanoma and other oncology indications. The company has incurred significant net losses, reporting $86.9 million in 2024 and $76.4 million in 2023. Developing bel-sar requires complex manufacturing, delivery via medical devices like Clearside Biomedical's SCS Microinjector, and extensive regulatory approvals.

Company is an immuno-oncology developer facing continuous operating losses and heavy reliance on preclinical programs.

Clene relies heavily on the commercialization of its lead drug candidate CNM-Au8, an emerging gold nanocrystal suspension for neurological diseases. The company faces significant risks from ongoing net losses, manufacturing self-dependence, regulatory approvals, and patient enrollment challenges.

Designer Brands faces intense competition in the footwear market and must adapt to rapid fashion trends. Sourcing merchandise internationally in places like China exposes the company to global supply risks. Controlling shareholder Jay L. Schottenstein and affiliates hold 67 percent of combined voting power through Class B shares.

Duluth Holdings faces high risks in customer acquisition, foreign supply chain reliance, and information technology security. The apparel retailer depends heavily on third-party manufacturers, seasonal holiday sales in the fourth quarter, and e-commerce channel performance.

The company relies heavily on Textron and Gulfstream aircraft, with operations heavily concentrated within two hours of its North Carolina headquarters. It faces significant labor pressures from pilot shortages and potential unionization, alongside complex capital and liquidity demands.

Omni Acquisition integration challenges, substantial indebtedness, and internal control weaknesses dominate the company risk profile.